Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human SERPINE1 expressed in E. Coli.|
|Storage buffer||PBS with 0.5% proprietary stabilizer|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:200 - 1:400|
|Immunohistochemistry (IHC)||1:200 - 1:1000|
|Western Blot (WB)||1:500 - 1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
MA5-17171 targets SERPINE1 in FACS, IHC, pep-ELISA, and WB applications and shows reactivity with Human samples.
The MA5-17171 immunogen is purified recombinant fragment of human SERPINE1 expressed in E. Coli.
MA5-17171 detects SERPINE1 which has a predicted molecular weight of approximately 45kDa.
This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma.
MA5-17171 was used in western blot to evaluate the LPA-producing enzyme autotaxin and LPAR3 as potential therapeutic targets in breast cancer patients
|Popnikolov NK,Dalwadi BH,Thomas JD,Johannes GJ,Imagawa WT||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (33:2237)||2012|
Endothelial plasminogen activator inhibitor; nexin, plasminogen activator inhibitor type 1; PAI; Plasminogen activator inhibitor 1; plasminogen activator inhibitor, type I; Plasminogen activator inhibitor-1 precursor (PAI-1) (Endothelial plasminogen activator inhibitor) (PAI); serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; serine (or cysteine) proteinase inhibitor, clade E, member 1; Serpin E1; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
PAI; PAI-1; PAI1; PLANH1; SERPINE1